

Cc: [redacted]@rivm.nl]; [redacted] [redacted]@rivm.nl]; [redacted]
To: [redacted]@rivm.nl]; [redacted]@hotmail.com]; [redacted]@hotmail.com]; arts infectieziektebestrijding Bonaire
 [redacted]@bonairegov.com]; [redacted]@bonairegov.com]; [redacted]@hoharuba.com]; [redacted]
 [redacted]@gmail.com]; [redacted]@outlook.com]; [redacted]@rivm.nl]; [redacted]
 [redacted]@sintmaartengov.org]; [redacted]@sintmaartengov.org]; [redacted]
 [redacted]@hotmail.com]; [redacted]@sintmaartengov.org]; [redacted]@sintmaartengov.org];
 [redacted]@despa.gov.aw]; [redacted]@statiagov.com]; [redacted]@statiagov.com];
 [redacted]@gobiernu.cw]; [redacted]@gobiernu.cw]; [redacted]
 [redacted]@gmail.com]; [redacted]@gmail.com]; [redacted]@gmail.com];
 [redacted]@bonairegov.com]; [redacted]@bonairegov.com]; [redacted]@gmail.com];
 [redacted]@sabagov.nl]; [redacted]@sabagov.nl]; [redacted]@gmail.com]; [redacted]
 [redacted]@xs4all.nl]; [redacted]@sintmaartengov.org]; [redacted]
 [redacted]@bonairegov.com]; [redacted]@gobiernu.cw]; [redacted]@gobiernu.cw]; [redacted] -
 [redacted]@klm.com]; [redacted]@hotmail.com]; [redacted]@hotmail.com]; [redacted]@statiagov.com]; [redacted]
 [redacted]@statiagov.com]; [redacted]@gmail.com]; [redacted]@statiagov.com]; [redacted]
 [redacted]@sintmaartengov.org]; [redacted]@sintmaartengov.org];
 [redacted]@despa.gov.aw]; [redacted]@despa.gov.aw]; [redacted]@gmail.com]; [redacted]@gmail.com]; [redacted]
 [redacted]@rivm.nl]; [redacted]@gobiernu.cw]

From: [redacted]
Sent: Mon 2/22/2021 2:04:23 PM
Subject: FW: ECDC RT Report 22 February 2021
Received: Mon 2/22/2021 2:04:23 PM
[RoundTableReport_20210222.pdf](#)

Beste collega,
 Bijgaand het epidemiologisch overzicht van ECDC met tevens een link naar een interessante studie in de Lancet
 over de bescherming na 1 dosis van het Pfizer vaccin.
 Met vriendelijke groet,

[redacted]

From: Duty EI 24/7 <support@ecdc.europa.eu>
Sent: maandag 22 februari 2021 13:04
To: John Ryan <[redacted]@ec.europa.eu>; [redacted]@ec.europa.eu' <[redacted]@ec.europa.eu>; SANTE CONSULT-C3
 <[redacted]@ec.europa.eu>; SANTE EWRS <[redacted]@ec.europa.eu>; SANTE HEOF COMMUNICATION <[redacted]@ec.europa.eu>;
 SANTE HEOF MEASURES <[redacted]@ec.europa.eu>; SANTE HEOF FACILITATOR
 <[redacted]@ec.europa.eu>; SANTE HEOF HEAD <[redacted]@ec.europa.eu>; [redacted]
 <[redacted]@ec.europa.eu>; DL_ECDC Experts <[redacted]@ecdc.europa.eu>; Director <[redacted]@ecdc.europa.eu>;
 DL_HoUs <[redacted]@ecdc.europa.eu>; Chief Scientist Support <[redacted]@ecdc.europa.eu>; International Relations
 <[redacted]@ecdc.europa.eu>; prU INFOSCAN <[redacted]@ecdc.europa.eu>; [redacted]@ec.europa.eu'
 <[redacted]@ec.europa.eu>; Duty EI 24/7 <support@ecdc.europa.eu>; PHE Manager Assistant
 <[redacted]@ecdc.europa.eu>; PHE Communication Group <[redacted]@ecdc.europa.eu>

Subject: ECDC RT Report 22 February 2021

Dear colleague,

We are pleased to share with you the ECDC Round Table Report. This report summarizes the daily roundtable discussion
 and provides update on threats detected and monitored by Epidemic Intelligence. This report contains information that
 might be sensitive or under verification. Its distribution is restricted to intended users only.

For further distribution, translation or copy of contents please contact [redacted]

Best regards,

[redacted]

On behalf of
 ECDC 24/7 duty team



European Centre for Disease Prevention and Control (ECDC)

Gustav III:s boulevard 40, 169 73 Solna, Sweden
Phone +46 (0)8 58 60 10 00 / Fax +46 (0)8 58 60 10 01
www.ecdc.europa.eu

Follow ECDC on:



Confidentiality Notice

If you are not the intended recipient of this message, you are hereby kindly requested, to, consecutively, refrain from disclosing its content to any third party, delete it, and inform its sender of the erroneous transmittal.